Cogent Biosciences, Inc.

COGT

Cogent Biosciences, Inc.

COGT

Insider Sentiment (TTM):

Last Purchase:2025-07-10Last Sale:2026-03-31Shares Purchased (TTM):0Shares Sold (TTM):10,814,642

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:179,175,052Shares Outstanding:162,194,778Institutional Ownership Pct.:110.47%

Earnings Market Reaction:

Filing Date:2026-08-10Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	181	241	312	125	128	126	98	97	88	216	53	87
Available For Sale Securities Debt Securities Curr…	611	625	589	266	110	120	189	238	275	220	212	192
Prepaid Expense And Other Assets Current	13	11	10	6	7	7	9	6	7	6	5	7
Assets Current	805	878	910	397	245	253	296	342	370	442	271	286
Available For Sale Securities Debt Securities Nonc…	-	-	-	-	-	-	-	10	27	0	7	34
Operating Lease Right Of Use Asset	23	18	18	19	19	20	20	21	21	22	22	22
Property Plant And Equipment Net	5	5	5	5	6	6	6	7	7	8	8	9
Restricted Cash Noncurrent	0	0	0	0	-	-	0	-	-	-	0	-
Other Assets Noncurrent	2	2	3	4	5	5	5	5	5	5	5	5
Assets	835	903	938	426	275	284	328	384	430	476	313	355
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	7	14	10	16	17	14	12	15	9	16	11	10
Operating Lease Liability Current	1	1	2	2	2	2	2	2	1	1	1	1
Liabilities Current	59	58	64	62	58	49	56	53	40	37	38	35
Long Term Debt Noncurrent	-	-	-	44	44	-	-	-	-	-	-	-
Convertible Debt Noncurrent	223	223	223	-	-	-	0	-	-	-	-	-
Operating Lease Liability Noncurrent	19	14	14	15	15	15	16	16	17	17	17	18
Other Liabilities Noncurrent	0	0	0	2	2	0	0	-	-	-	-	-
Liabilities	302	295	301	123	120	65	72	69	57	54	56	53
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,850	1,829	1,735	1,280	1,052	1,042	1,005	995	980	862	801	792
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	0	0	0	0	0	1	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-1,382	-1,286	-1,188	-1,086	-1,005	-931	-859	-792	-721	-662	-604	-549
Stockholders Equity	532	608	636	302	155	219	256	315	373	422	258	303
Liabilities And Stockholders Equity	835	903	938	426	275	284	328	384	430	476	313	355
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	-	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	150	300	150
Common Stock Shares Issued	172	171	161	140	114	114	110	110	109	96	86	86
Shares Outstanding	172	171	161	140	114	114	110	110	109	96	86	86
Share Based Compensation Arrangement By Share Base…	-	-	-	-	-	0	-	-	-	-	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-5.46%	3.03%	7.52%	-	-	-	-	-	-	-	-	-
2025	15.74%	51.06%	156.81%	6.34%	24.65%	33.19%	171.39%	162.35%	147.50%	-9.62%	-3.32%	-7.66%
2024	3.22%	8.63%	22.68%	15.98%	17.71%	29.27%	-14.35%	-24.08%	-10.31%	2.43%	-37.48%	-30.19%
2023	-	-	-	-	-	-	-6.24%	-30.82%	-48.53%	-14.80%	-10.53%	-0.80%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	13.57	15.14	14.23	6.38	4.19	5.13	5.32	6.44	9.25	12.05	7.09	8.24
Quick Ratio	13.36	14.94	14.08	6.28	4.07	4.98	5.15	6.32	9.08	11.88	6.96	8.04
Working Capital	745.52M	819.82M	846.40M	335.00M	186.59M	203.57M	240.76M	288.48M	329.97M	405.22M	232.60M	251.23M
Leverage & Debt
Debt to Equity	0.57	0.49	0.47	0.41	0.77	0.30	0.28	0.22	0.15	0.13	0.22	0.17
Interest Coverage TTM	-75.14	-84.69	-108.87	-173.49	-954.34	-	-	-	-	-	-	-
Debt Ratio	0.36	0.33	0.32	0.29	0.44	0.23	0.22	0.18	0.13	0.11	0.18	0.15
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-2.21	-2.18	-2.55	-2.14	-2.48	-2.38	-2.46	-2.20	-2.29	-2.24	-2.42	-2.06
Free Cash Flow Per Share TTM	-1.69	-1.77	-2.07	-1.31	-1.47	-1.97	-2.01	-1.74	-1.79	-1.78	-1.96	-1.66
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	32.77%	31.47%	28.56%	21.49%	25.12%	27.02%	32.98%	36.38%	44.30%	43.17%	37.20%	41.52%
EPS Growth (1Y)	-11.12%	-8.16%	3.58%	-2.70%	8.48%	6.28%	1.99%	6.67%	8.69%	6.82%	1.17%	14.28%
Valuation Metrics
P/E TTM	-17.55	-17.62	-13.92	-6.71	-2.89	-2.52	-3.17	-4.91	-3.68	-3.00	-2.43	-4.73
P/B TTM	12.43	10.27	7.19	6.53	5.30	3.10	3.16	3.78	2.24	1.51	1.82	2.77
Market Cap	6.62B	6.24B	4.58B	1.98B	821.87M	678.71M	810.08M	1.19B	836.59M	637.09M	468.39M	840.12M
Enterprise Value	6.66B	6.22B	4.87B	1.89B	738.22M	552.71M	711.92M	1.09B	748.37M	421.29M	415.16M	753.31M
Calculated Values
Free Cash Flow TTM	-289.12M	-287.10M	-266.83M	-180.51M	-168.42M	-222.82M	-208.36M	-192.10M	-177.93M	-168.40M	-156.42M	-143.41M
Net Debt	41.87M	-18.45M	289.70M	-81.38M	-83.65M	-126.00M	-98.17M	-97.05M	-88.22M	-215.80M	-53.23M	-86.81M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-31Sale

Owner: Fairmount, Funds Manageme…

Title: -

Shares: 7,000,000

Price/Share: $34.66

Value: $242,620,000.00

Shares Owned: 5,503,418

Relationship: Director

Ownership: Indirect

2026-01-22Sale

Owner: Fairmount, Funds Manageme…

Title: -

Shares: 3,500,000

Price/Share: $36.40

Value: $127,400,000.00

Shares Owned: 5,503,418

Relationship: Director

Ownership: Indirect

2025-12-26Sale

Owner: Robinson, John Edward

Title: Chief Scientific Officer

Shares: 90,000

Price/Share: $38.74

Value: $3,486,600.00

Shares Owned: 140,002

Relationship: Officer

Ownership: Direct

2025-12-26Sale

Owner: Kearns, Evan

Title: Chief Legal Officer

Shares: 65,000

Price/Share: $38.70

Value: $2,515,500.00

Shares Owned: 109,398

Relationship: Officer

Ownership: Direct

2025-12-26Sale

Owner: Green, John L.

Title: Chief Financial Officer

Shares: 77,000

Price/Share: $38.68

Value: $2,978,360.00

Shares Owned: 131,834

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-31	Fairmount, Funds Manageme…	Director	-	Indirect	Sale	7,000,000	34.66	$242,620,000.00	5,503,418	4
2026-01-22	Fairmount, Funds Manageme…	Director	-	Indirect	Sale	3,500,000	36.40	$127,400,000.00	5,503,418	4
2025-12-26	Robinson, John Edward	Officer	Chief Scientific Officer	Direct	Sale	90,000	38.74	$3,486,600.00	140,002	4
2025-12-26	Kearns, Evan	Officer	Chief Legal Officer	Direct	Sale	65,000	38.70	$2,515,500.00	109,398	4
2025-12-26	Green, John L.	Officer	Chief Financial Officer	Direct	Sale	77,000	38.68	$2,978,360.00	131,834	4
2025-12-26	Sachs, Jessica	Officer	Chief Medical Officer	Direct	Sale	82,642	38.70	$3,198,245.40	133,938	4
2025-07-10	Fairmount, Funds Manageme…	Director	-	Indirect	Purchase	2,777,777	9.00	$24,999,993.00	9,003,418	4
2025-01-14	Pinnow, Cole	Officer	Chief Commercial Officer	Direct	Purchase	43,750	7.60	$332,500.00	45,848	4
2023-06-09	Fairmount, Funds Manageme…	TenPercentOwner,Other	-	Indirect	Purchase	800,000	12.00	$9,600,000.00	3,272,124	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

110.47%

Inst. Shares: 179,175,052

Shares Outstanding: 162,194,778

2025-12-31

129.03%

Inst. Shares: 166,316,959

Shares Outstanding: 128,899,408

2025-09-30

114.46%

Inst. Shares: 157,444,637

Shares Outstanding: 137,550,159

2025-06-30

116.95%

Inst. Shares: 133,864,884

Shares Outstanding: 114,466,080

2025-03-31

113.77%

Inst. Shares: 128,909,942

Shares Outstanding: 113,307,940

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	179,175,052	162,194,778	110.47%
2025-12-31	166,316,959	128,899,408	129.03%
2025-09-30	157,444,637	137,550,159	114.46%
2025-06-30	133,864,884	114,466,080	116.95%
2025-03-31	128,909,942	113,307,940	113.77%
2024-12-31	119,924,993	103,856,611	115.47%
2024-09-30	121,291,963	110,165,580	110.10%
2024-06-30	125,495,784	99,240,030	126.46%
2024-03-31	108,342,838	94,804,659	114.28%
2023-12-31	89,344,350	79,657,942	112.16%
2023-09-30	90,275,127	86,165,951	104.77%
2023-06-30	81,300,114	74,753,269	108.76%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Cogent Biosciences, Inc. (COGT) — SEC Financial Statements & Analysis

Cogent Biosciences, Inc. (COGT) is a pharmaceutical preparations company, incorporated in DE. Cogent Biosciences, Inc. trades on Nasdaq as: COGT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Cogent Biosciences, Inc. reported a Debt-to-Equity ratio of 0.57x, a Price-to-Book (P/B) ratio of 12.43x (TTM), at a market cap of $6.62B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.57x
P/B TTM: 12.43x
Market Cap: $6.62B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Cogent Biosciences, Inc. in?

Cogent Biosciences, Inc. (COGT) operates in the Pharmaceutical Preparations industry.

What is COGT's market cap?

Cogent Biosciences, Inc. (COGT) has a market capitalization of $6.62B as of 2026-06-30.

What exchange does COGT trade on?

Cogent Biosciences, Inc. (COGT) trades on the Nasdaq.

Where is Cogent Biosciences, Inc. incorporated?

Cogent Biosciences, Inc. is incorporated in DE.